Sökning: id:"swepub:oai:lup.lub.lu.se:5df68ddb-09dc-42a5-8e02-cb1f9c8dbbca" >
Three-year data fro...
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus : Long-term efficacy with or without rescue therapy
-
- Home, Philip D. (författare)
- University of Newcastle upon Tyne
-
- Ahrén, Bo (författare)
- Lund University,Lunds universitet,Diabetes,Forskargrupper vid Lunds universitet,Lund University Research Groups
-
- Reusch, Jane E.B. (författare)
- VA Eastern Colorado Health Care System
-
visa fler...
-
- Rendell, Marc (författare)
- Creighton University
-
- Weissman, Peter N. (författare)
- No affiliation available (private)
-
- Cirkel, Deborah T (författare)
- GlaxoSmithKline (GSK), UK
-
- Miller, Diane (författare)
- GlaxoSmithKline
-
- Ambery, Philip (författare)
- GlaxoSmithKline
-
- Carr, Molly C. (författare)
- GlaxoSmithKline
-
- Nauck, Michael A. (författare)
- Ruhr-University Bochum
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2017
- 2017
- Engelska 12 s.
-
Ingår i: Diabetes Research and Clinical Practice. - : Elsevier BV. - 0168-8227. ; 131, s. 49-60
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims Diabetes therapies that provide durable glycaemic control for people with type 2 diabetes mellitus (T2DM) are needed. We present efficacy results of albiglutide, a glucagon-like peptide-1 receptor agonist, in people with T2DM over a 3-year period. Methods Five of the 8 HARMONY phase 3 trials, comparing albiglutide with other therapies or placebo across a spectrum of clinical care, lasted for a preplanned 3 years. Participants with uncontrolled hyperglycaemia who met predetermined criteria could receive rescue medication. The ability to remain on study medication without needing additional rescue was an efficacy measure. Glycaemic measures and body weight were analysed in 2 populations: those who remained rescue-free and all participants. Results Participants (n = 3132) were randomised to albiglutide or comparator. A greater proportion of participants who received albiglutide remained rescue-free (55–71%) compared with placebo (35–51%; p < 0.001 to p = 0.002). The proportion of rescue-free participants with albiglutide did not differ from glimepiride or insulin glargine, was higher than with sitagliptin (p = 0.013), and lower than with pioglitazone (p = 0.045). At 3 years, albiglutide was associated with clinically significant reductions in hyperglycaemia (eg, rescue-free participants: HbA1c −0.52% [SE0.11] to −0.98% [0.12]; −5.7 mmol/mol [1.2] to −10.7 mmol/mol [1.3] and all participants: HbA1c −0.29% [0.11] to − 0.92% [0.13]; −3.2 mmol/mol [1.2] to −10.1 mmol/mol [1.4]). Albiglutide was also associated with modest reductions in body weight vs pioglitazone, glimepiride, and insulin glargine, which were associated with weight gain. Conclusion These 3-year efficacy data support long-term use of albiglutide in the management of people with T2DM. ClinicalTrials.gov NCT00849056, NCT00849017, NCT00838903, NCT00838916, NCT00839527.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Albiglutide
- Diabetes mellitus
- Durability
- Efficacy
- Glucagon-like peptide-1
- Incretins
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Home, Philip D.
-
Ahrén, Bo
-
Reusch, Jane E.B ...
-
Rendell, Marc
-
Weissman, Peter ...
-
Cirkel, Deborah ...
-
visa fler...
-
Miller, Diane
-
Ambery, Philip
-
Carr, Molly C.
-
Nauck, Michael A ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Diabetes Researc ...
- Av lärosätet
-
Lunds universitet